CSPC Pharmaceutical Group Limited
CSPCY · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.85 | -0.15 | -0.24 | 0.09 |
| FCF Yield | 0.33% | -1.44% | 1.07% | 2.29% |
| EV / EBITDA | 23.36 | 19.03 | 14.23 | 41.42 |
| Quality | ||||
| ROIC | -0.38% | 4.18% | 7.87% | 2.12% |
| Gross Margin | 65.62% | 68.19% | 71.57% | 246.25% |
| Cash Conversion Ratio | 0.16 | 2.38 | 0.47 | 0.43 |
| Growth | ||||
| Revenue 3-Year CAGR | -10.81% | -4.35% | -1.50% | 1.68% |
| Free Cash Flow Growth | 137.38% | -200.00% | -60.36% | 347.15% |
| Safety | ||||
| Net Debt / EBITDA | -2.03 | -2.51 | -1.76 | -6.30 |
| Interest Coverage | 118.65 | 0.00 | 0.00 | 198.43 |
| Efficiency | ||||
| Inventory Turnover | 0.22 | 1.48 | 1.34 | 2.29 |
| Cash Conversion Cycle | 547.75 | 71.33 | 70.31 | 127.15 |